Stock Track | Allogene Therapeutics Stock Plunges After Disappointing Earnings Report

Stock Track11-09

Allogene Therapeutics Inc. (ALLO) saw its stock price plummet by 6.58% on November 8, 2024, following the release of its earnings report for the quarter ended January 1, 2024.

The biotechnology company reported a wider-than-expected adjusted loss of $0.32 per share for the quarter, missing analysts' expectations of a $0.33 loss per share. The company also failed to generate any revenue, while analysts had forecast revenue of $12,930.

Allogene Therapeutics reported a quarterly loss of $66.29 million, reflecting the company's ongoing investments in research and development as it continues to advance its pipeline of experimental cancer treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191888401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191888401","market":"us","top_or_hot":-1,"title":"Stock Track | Allogene Therapeutics Stock Plunges After Disappointing Earnings Report","media":"Stock Track","content":"<p>Allogene Therapeutics Inc. (ALLO) saw its stock price plummet by 6.58% on November 8, 2024, following the release of its earnings report for the quarter ended January 1, 2024.</p>\n\n<p>The biotechnology company reported a wider-than-expected adjusted loss of $0.32 per share for the quarter, missing analysts' expectations of a $0.33 loss per share. The company also failed to generate any revenue, while analysts had forecast revenue of $12,930.</p>\n\n<p>Allogene Therapeutics reported a quarterly loss of $66.29 million, reflecting the company's ongoing investments in research and development as it continues to advance its pipeline of experimental cancer treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Allogene Therapeutics Stock Plunges After Disappointing Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Allogene Therapeutics Stock Plunges After Disappointing Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-09 00:48 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Allogene Therapeutics Inc. (ALLO) saw its stock price plummet by 6.58% on November 8, 2024, following the release of its earnings report for the quarter ended January 1, 2024.\nThe biotechnology ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALLO","symbol_name":"Allogene Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1191888401","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191888401","pubTimestamp":1731084513,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Allogene Therapeutics Inc.  saw its stock price plummet by 6.58% on November 8, 2024, following the release of its earnings report for the quarter ended January 1, 2024.The biotechnology company reported a wider-than-expected adjusted loss of $0.32 per share for the quarter, missing analysts' expectations of a $0.33 loss per share. The company also failed to generate any revenue, while analysts had forecast revenue of $12,930.Allogene Therapeutics reported a quarterly loss of $66.29 million, ref","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALLO":"Allogene Therapeutics Inc."},"translate_title":"股票追踪Allogene Therapeutics股价在令人失望的收益报告后暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1},"content_text":"Allogene Therapeutics Inc. (ALLO) saw its stock price plummet by 6.58% on November 8, 2024, following the release of its earnings report for the quarter ended January 1, 2024.\nThe biotechnology company reported a wider-than-expected adjusted loss of $0.32 per share for the quarter, missing analysts' expectations of a $0.33 loss per share. The company also failed to generate any revenue, while analysts had forecast revenue of $12,930.\nAllogene Therapeutics reported a quarterly loss of $66.29 million, reflecting the company's ongoing investments in research and development as it continues to advance its pipeline of experimental cancer treatments.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191888401"}